Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.

To determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.

Inclusion Criteria:

• The subject is at least 50 years of age.
• The subjects' general health is adequate to comply with study procedures.
• The subject has been scheduled for a shunt placement procedure for the treatment of NPH.

Exclusion Criteria:

• The subject has a contraindication for MRI or PET.
• The subject is pregnant or lactating.
• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol or to any of the excipients.
• The subject has participated in any clinical study using an investigational agent within 30 days of dosing.